Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Stares and Prayers.

Spencer LG.

Health Commun. 2019 Apr 24:1-3. doi: 10.1080/10410236.2019.1598617. [Epub ahead of print] No abstract available.

PMID:
31018702
2.

Sarcoidosis in the UK: insights from British Thoracic Society registry data.

Thillai M, Chang W, Chaudhuri N, Forrest I, Ho LP, Lines S, Maher TM, Spencer LG, Spiteri M, Coker R.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000357. doi: 10.1136/bmjresp-2018-000357. eCollection 2019.

3.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

4.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

5.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

6.

The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases.

Cotton CV, Spencer LG, New RP, Cooper RG.

Rheumatology (Oxford). 2017 Aug 1;56(8):1264-1271. doi: 10.1093/rheumatology/kew320. Review.

7.

Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis.

Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL.

J Adv Nurs. 2015 May;71(5):1055-65. doi: 10.1111/jan.12587. Epub 2014 Dec 23.

8.

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA).

Yorke J, Spencer LG, Duck A, Ratcliffe S, Kwong GN, Longshaw MS, Belkin A, Swigris JJ.

BMJ Open Respir Res. 2014 May 13;1(1):e000024. doi: 10.1136/bmjresp-2014-000024. eCollection 2014.

9.

Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion.

Thickett DR, Kendall C, Spencer LG, Screaton N, Wallace WA, Pinnock H, Bott J, Pigram L, Watson S, Millar AB.

Thorax. 2014 Dec;69(12):1136-40. doi: 10.1136/thoraxjnl-2014-206284. Epub 2014 Oct 21.

PMID:
25335486

Supplemental Content

Loading ...
Support Center